Individuals with severe mental illnesses such as schizophrenia or bipolar disorder have a reduced life expectancy compared with the general population, especially related to cardiovascular disease.1-3 Furthermore, this gap has increased in recent years, especially with regard to schizophrenia3,4 and bipolar affective disorder.4 The standardised mortality ratio for death within 1 year of psychiatric in-patient care for people with schizophrenia increased from 1.6 in people discharged in 1999 to 2.2 in those discharged in 2006, and for people with bipolar disorder it increased from 1.3 in 1999 to 1.9 in 2006.5 The aetiology of this excess cardiovascular disease is multifactorial and most likely includes genetic and lifestyle factors as well as disease-specific and treatment effects.6

People with severe mental illness are likely to have a number of modifiable cardiovascular risk factors. The metabolic syndrome is a constellation of cardiovascular risk factors that helps to identify individuals at risk of cardiovascular disease and type 2 diabetes. It comprises a combination of physical and metabolic abnormalities which can be identified by abnormal values for: central obesity, hypertension, high-density lipoprotein (HDL) cholesterol, triglycerides, and fasting plasma glucose.7 These abnormal clinical and metabolic findings act to increase the risk of cardiovascular disease. It has been consistently shown that there is an increased prevalence of metabolic syndrome in people with psychiatric illness, with one large study reporting that 52% of individuals in a population of psychiatric out-patients met the US National Cholesterol Education Program–Adult Treatment Panel III (NCEP ATP III) criteria for metabolic syndrome.8 In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, over 30% of patients met the NCEP ATP III criteria for metabolic syndrome at baseline.9

Weight gain is a well-established side-effect of antipsychotic medication, in particular certain second-generation antipsychotic medications. The cumulative incidence of patients becoming overweight on clozapine exceeds 50%, with a mean weight gain of 4.45 kg at 10 weeks of treatment,10 and a mean weight gain of 4.15 kg for olanzapine and 2.1 kg for risperidone.11 There is an increased risk of dyslipidaemia, insulin resistance, hyperglycaemia and new-onset type 2 diabetes, and this risk is particularly associated with the use of olanzapine and clozapine.12-16

The need for screening and monitoring cardiovascular risk factors in psychiatric populations is well documented, however, the evaluation of screening practices by clinicians has been shown to be suboptimal.13,16 In this study, we sought to ascertain the prevalence and associations of metabolic syndrome in a typical cohort of individuals with chronic enduring mental illness attending the psychiatric day centres within a catchment area mental health service. We wished to evaluate whether there was an increased prevalence of metabolic syndrome in individuals on antipsychotic medication, on high-dose antipsychotics and on antipsychotic polypharmacy. We also sought to assess the prevalence of the individual metabolic risk factors for
cardiovascular disease in our study population and the extent to which they were being screened for.

**Method**

Participants who lived in the community and who were attending one of the three psychiatric day centres in the West Galway adult mental health services were recruited over a 4-week period in July 2011. Two of the day centres were located in an urban setting and the third was in a rural setting. All of the 136 individuals who were attending any of the three centres over that period were asked to participate. Completed data were obtained from 100 patients (73.5%) and included in the study; 36 individuals were not included in the study, as complete anthropomorphic data could not be obtained from them.

Diagnoses were made in accordance with ICD-10 diagnostic criteria from clinical interviews and review of the medical notes. Clinical and demographic data including age, gender and ethnicity were collected from each individual. Treatment with high-dose antipsychotic medication was defined as receiving more than 100% of the British National Formulary maximum dose per day. For patients on more than one medication, this was calculated by converting their prescribed dose to its percentage of the maximum recommended dose for each drug and then summing the percentages.

The International Diabetes Federation (IDF) definition of metabolic syndrome (Table 1) was used. In addition, glycated haemoglobin (HbA1c) > 6% was used to indicate impaired fasting glucose and was deemed to meet the criteria for metabolic syndrome. This was applied to individuals who had blood drawn by their general practitioners (GPs) in the previous 12 months and who were screened with an HbA1c level rather than with a fasting plasma glucose level (n = 16).

The medical records (both hospital and primary care) of these individuals were examined for evidence of measurement of fasting glucose, HbA1c, triglyceride or HDL cholesterol levels. Those who did not have these parameters assessed in the previous 12 months had morning blood samples drawn after a period of fasting of at least 12 h and tested for: fasting plasma glucose, HDL cholesterol, triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol and HbA1c.

Although anthropomorphic measurements such as body mass index (BMI) could be derived from some of the patients’ notes, this information was often insufficient for the purposes of diagnosing metabolic syndrome (e.g. few patients had a documented waist circumference). Therefore, all patients were assessed for anthropomorphic measurements for the present study. Height, weight and waist circumference were all measured using standardised techniques. The waist circumference was measured at the midpoint between the lower rib and the iliac crest with the patient standing. Standardised techniques were used to measure blood pressure. A medical history was obtained from each individual and included items such as psychiatric history, medical history (including hypertension, diabetes mellitus and dyslipidaemia), medication, family history (including ischaemic heart disease), smoking and exercise habits.

**Statistical analysis**

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) 18.0 for Windows. The student t-test for parametric data and the χ²-test for non-parametric data were employed. All statistical tests were two-sided and the z-level for statistical significance was 0.05.

**Results**

The mean age of the participants was 58 years (s.d. = 12.3) and 55% of the study population were female. Most patients had a diagnosis of schizophrenia (50%), recurrent depressive disorder (31%) and bipolar affective disorder (9%). Overall, 85% of participants were treated with antipsychotic medication, with 79% of patients taking atypical antipsychotics, most frequently olanzapine (34%), quetiapine (23%) and clozapine (9%). In total, 63% of patients were treated with atypical antipsychotic monotherapy and 6% were treated with typical antipsychotic

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Diagnostic criteria for metabolic syndrome used in the study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factor</td>
<td>Defining measure</td>
</tr>
<tr>
<td>Central obesity</td>
<td>Waist circumference</td>
</tr>
<tr>
<td>Men</td>
<td>≥ 94 cm for Europid men, ≥ 90 cm for South Asian men</td>
</tr>
<tr>
<td>Women</td>
<td>≥ 80 cm for Europid women, ≥ 80 cm for South Asian women</td>
</tr>
<tr>
<td>Plus any two of the following:</td>
<td></td>
</tr>
<tr>
<td>raised triglycerides</td>
<td>≥ 1.7 OR specific treatment for this lipid abnormality</td>
</tr>
<tr>
<td>reduced HDL cholesterol</td>
<td></td>
</tr>
<tr>
<td>men</td>
<td>≤ 1.03 OR specific treatment for this lipid abnormality</td>
</tr>
<tr>
<td>women</td>
<td>≤ 1.29 OR specific treatment for this lipid abnormality</td>
</tr>
<tr>
<td>raised blood pressure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg OR treatment of previously diagnosed hypertension</td>
</tr>
<tr>
<td>raised fasting plasma glucose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 5.6 mmol/l OR previously diagnosed type 2 diabetes</td>
</tr>
</tbody>
</table>

HDL, high-density lipoprotein.

Reproduced with permission from Alberti et al. © International Diabetes Federation.

https://doi.org/10.1192/pb.bp.111.037374 Published online by Cambridge University Press
monotherapy; 16% were on a high-dose antipsychotic and 32% were taking more than one antipsychotic. Fifty-five patients (55%) met the IDF criteria for metabolic syndrome. The clinical characteristics of patients with and without the metabolic syndrome are presented in Table 2. Relatively more women than men met the diagnostic criteria for metabolic syndrome, but this did not reach statistical significance ($P = 0.089$). There was no difference in the prevalence of metabolic syndrome by psychiatric diagnosis. The means of most metabolic parameters were significantly elevated in those patients fulfilling criteria for the metabolic syndrome. However, the mean total cholesterol levels were significantly lower in the group of patients with the metabolic syndrome than in those without the metabolic syndrome, presumably because 40% of individuals with the syndrome were on statin therapy, compared with 13% without metabolic syndrome on statin therapy.

Overall, 54% of patients on atypical antipsychotics, 50% of those on antipsychotic polypharmacy and 31% of those on high-dose antipsychotic medication met the criteria for metabolic syndrome; however, there was no statistically significant association between each of these variables and the metabolic syndrome. Indeed, those taking high-dose antipsychotic medication were actually less likely to have metabolic syndrome. Most of the patients taking clozapine (78%) or olanzapine (62%) met the criteria for metabolic syndrome, although this was not a statistically significant association. Eleven per cent of individuals were on antidepressant monotherapy and 64% ($n = 7$) of those patients met the criteria for the metabolic syndrome.

### Table 2 Demographics and clinical characteristics of individuals with and without metabolic syndrome

<table>
<thead>
<tr>
<th></th>
<th>Metabolic syndrome (n = 55; 55%)</th>
<th>No metabolic syndrome (n = 45; 45%)</th>
<th>$\chi^2$-test</th>
<th>d.f.</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years: mean</td>
<td>59.7 (s.d. = 12.4; range 26–90)</td>
<td>56.8 (s.d. = 12.2; range 34–87)</td>
<td>1.163*</td>
<td>98</td>
<td>0.255*</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>20 (45.5)</td>
<td>24 (54.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>35 (62.5)</td>
<td>21 (37.5)</td>
<td>2.893</td>
<td>1</td>
<td>0.089</td>
</tr>
<tr>
<td>Diagnosis, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>26 (52)</td>
<td>24 (48)</td>
<td>0.364</td>
<td>1</td>
<td>0.564</td>
</tr>
<tr>
<td>Depression</td>
<td>18 (58.1)</td>
<td>13 (41.9)</td>
<td>0.170</td>
<td>1</td>
<td>0.680</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>5 (55.6)</td>
<td>4 (44.4)</td>
<td>0.01</td>
<td>1</td>
<td>0.972</td>
</tr>
<tr>
<td>Other non-psychotic disorder</td>
<td>6 (60)</td>
<td>4 (40)</td>
<td>0.112</td>
<td>1</td>
<td>0.738</td>
</tr>
<tr>
<td>Treatment, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antipsychotic</td>
<td>46 (54.1)</td>
<td>39 (45.9)</td>
<td>0.178</td>
<td>1</td>
<td>0.673</td>
</tr>
<tr>
<td>Typical antipsychotic monotherapy</td>
<td>3 (50)</td>
<td>3 (50)</td>
<td>0.064</td>
<td>1</td>
<td>0.800</td>
</tr>
<tr>
<td>Atypical antipsychotic</td>
<td>42 (54.4)</td>
<td>36 (45.6)</td>
<td>0.049</td>
<td>1</td>
<td>0.808</td>
</tr>
<tr>
<td>Antipsychotic polypharmacy</td>
<td>16 (50)</td>
<td>16 (50)</td>
<td>0.475</td>
<td>1</td>
<td>0.491</td>
</tr>
<tr>
<td>High-dose antipsychotic</td>
<td>5 (31.3)</td>
<td>11 (68.8)</td>
<td>4.341</td>
<td>1</td>
<td>0.034</td>
</tr>
<tr>
<td>Clozapine</td>
<td>7 (77.8)</td>
<td>2 (22.2)</td>
<td>2.073</td>
<td>1</td>
<td>0.150</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>21 (61.8)</td>
<td>13 (38.2)</td>
<td>0.952</td>
<td>1</td>
<td>0.329</td>
</tr>
<tr>
<td>Smoking, yes</td>
<td>25 (58.1)</td>
<td>18 (41.8)</td>
<td>1.211</td>
<td>2</td>
<td>0.546</td>
</tr>
<tr>
<td>Exercise &gt;3×20 min/week</td>
<td>19 (45.2)</td>
<td>23 (54.8)</td>
<td>2.760</td>
<td>1</td>
<td>0.071</td>
</tr>
<tr>
<td>Family history of CVD</td>
<td>21 (52.5)</td>
<td>19 (47.5)</td>
<td>0.168</td>
<td>1</td>
<td>0.682</td>
</tr>
<tr>
<td>Family history of diabetes</td>
<td>13 (61.9)</td>
<td>8 (38.1)</td>
<td>0.512</td>
<td>1</td>
<td>0.47</td>
</tr>
</tbody>
</table>

CVD, cardiovascular disease.

a. $\chi^2$-test.

### Table 3 Participants who met individual criteria for metabolic syndrome

<table>
<thead>
<tr>
<th></th>
<th>n (%)</th>
<th>$\chi^2$</th>
<th>d.f.</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (n = 55)</td>
<td>Male (n = 44)</td>
<td>Female (n = 56)</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>55</td>
<td>20 (43.5)</td>
<td>35 (62.5)</td>
<td>2.893</td>
</tr>
<tr>
<td>Central obesity</td>
<td>88</td>
<td>36 (81.8)</td>
<td>52 (92.8)</td>
<td>2.843</td>
</tr>
<tr>
<td>Hypertension</td>
<td>41</td>
<td>16 (36.4)</td>
<td>25 (44.6)</td>
<td>0.833</td>
</tr>
<tr>
<td>Hypertriglyceridaemia</td>
<td>43</td>
<td>20 (45.5)</td>
<td>23 (41.1)</td>
<td>0.216</td>
</tr>
<tr>
<td>Low HDL</td>
<td>29</td>
<td>11 (25)</td>
<td>18 (32.1)</td>
<td>0.506</td>
</tr>
<tr>
<td>Glucose dysregulation</td>
<td>32</td>
<td>14 (21.8)</td>
<td>18 (32.1)</td>
<td>0.070</td>
</tr>
</tbody>
</table>

HDL, high-density lipoprotein.

a. $\chi^2$-test between males and females.
evidence of glucose dysregulation (impaired glucose tolerance or undiagnosed diabetes mellitus, or diagnosis of diabetes mellitus, or HbA1c > 6%).20 This is in contrast to the figure of 14% for previously diagnosed diabetes mellitus in our study population. Whereas 28% of our study population were on treatment for hypercholesterolaemia and 33% were on anti-hypertensive medication, 47% of patients with metabolic syndrome were being treated with anti-hypertensive medication.

A substantial proportion (44%) of the individuals in this study had not been monitored for metabolic parameters in the previous year and this included 35% of the total population who were taking antipsychotic medication (Fig. 1). This cohort of unscreened individuals had a prevalence rate of 43% for the metabolic syndrome, with 30% identified with glucose dysregulation, including two new cases of diabetes mellitus. The rate of dyslipidaemia was greater than 50% in these individuals.

Discussion

There was a high prevalence rate of metabolic syndrome in this typical cohort of individuals with chronic enduring mental illness attending day centres within the catchment area service. Over half of these individuals (55%) met the criteria for metabolic syndrome, which is over twice the prevalence in the general Irish population.21 This prevalence rate is similar to a previous study which examined patients on clozapine therapy and identified 46% prevalence rate for the metabolic syndrome.22

There was a similar prevalence of the metabolic syndrome in individuals with a history of non-psychotic disorders and those with a history of psychotic disorders. This study sample is representative of a typical cohort of patients with chronic enduring mental illness and there is a significantly elevated prevalence of the metabolic syndrome across a broad range of psychiatric disorders. This pattern of metabolic syndrome existing across psychiatric disorders has been reported in other studies.9,23,24 This study provides further evidence that chronic enduring mental illness in general should be considered a risk factor for metabolic syndrome. A similar prevalence rate of metabolic syndrome (using the IDF criteria) of 51% in patients with schizophrenia was reported elsewhere25 and has been replicated in other studies such as the finding of a prevalence rate of 49% in individuals with a duration of schizophrenia of more than 20 years.26 The high rate of metabolic syndrome in our study regardless of diagnostic group or the use of antipsychotic medication indicates that it is chronic mental illness per se which is associated with metabolic syndrome rather than a psychotic diagnosis or the use of atypical antipsychotic medication. This may be due to the poor self-care associated with this patient cohort, including unhealthy diet and sedentary lifestyle.

Our study demonstrated similar prevalence rates of the metabolic syndrome in individuals treated with antipsychotics (54%) and those not on antipsychotic medications (46%). This is similar to other studies which showed prevalence rates of 48% for the metabolic syndrome in individuals treated with antipsychotics.14

Strengths of the study are the screening of a cohort attending day centres in a catchment area service and thus representative of patients with chronic enduring mental illness in the region, rather than confined to a particular diagnosis or type of medication.

Limitations of the study include the cross-sectional design and the lack of a non-medicated control group or longitudinal assessment. This study did not assess the severity of symptoms, which may have been a contributing factor to the presence of the metabolic syndrome. Other confounding factors which may act as independent risk factors for metabolic syndrome (e.g. poor diet) were not assessed in this study population.

Despite the high prevalence of cardiovascular risk factors in patients with chronic enduring mental illness, such patients are likely to suffer from a fragmented and inconsistent approach to their physical healthcare. It has been identified that people with long-term mental illness tend to seek medical attention only in crisis situations and have limited access to general healthcare, with less opportunity for cardiovascular disease risk screening and prevention.27 This, allied to the high rates of metabolic syndrome, poses a significant public health challenge.
syndrome in this cohort, highlights the need for improved integration in the screening for and management of physical risk factors. It is particularly important to improve the collaboration between primary and secondary care in the clinical care of these individuals. A recent study by our group has indicated that the majority of GPs were willing to take over the medical management of metabolic dysregulation emerging from antipsychotic prescribing in secondary care. Given the high prevalence of metabolic risk factors in individuals with chronic enduring mental illness regularly attending mental health services, it is important that mental health services take advantage of the opportunity to improve their care by implementing protocols for the screening, pharmacological (including alteration of psychotropic medication) and non-pharmacological management of these risk factors and referral to primary or secondary care as required. As a minimum, individuals who are treated with antipsychotics should be systematically screened according to guidelines. The results of this study which showed high prevalence rates for metabolic syndrome across a range of psychotic and affective disorders indicates that it could be beneficial to extend such guidelines to the wider cohort of patients with chronic enduring mental illness. Twenty-five patients with metabolic syndrome in our cohort smoked (45.5%). Effective smoking cessation programmes would be an important intervention in reducing this particular cardiovascular risk factor.

A recent systematic review demonstrated that there is a paucity of research on the impact of general physical health advice on the outcomes of physical health awareness or physical health behaviour in people with serious mental illness. There is a general consensus that physical activity has a mild to moderately favourable effect on many metabolic and cardiovascular risk factors that constitute or are related to metabolic syndrome. This is supported by our study which demonstrated that 55% of individuals who exercised for more than 20 min at a time on more than three occasions in a week did not meet the criteria for metabolic syndrome. Physical health and diet educational programmes as non-pharmacological interventions for weight gain and other metabolic abnormalities should be implemented in the community setting. This will involve initiation of programmes which can be adapted to the individuals’ personal preferences and their personal attitudes towards physical exercise and dietary restrictions.

The high prevalence of the metabolic syndrome in those with a history of chronic enduring mental illness indicates that this population would benefit from regular screening for and the intensive management of cardiometabolic risk factors to reduce their morbidity and mortality secondary to cardiovascular disease.

**Funding**

Research Support Fund, National University of Ireland, Galway.

**Acknowledgements**

We thank the staff and patients of the Ceim Eile and Danesfield psychiatric day centres in Galway city and the staff and patients of the Elm Tree Centre, Clifden, Co. Galway for their assistance in the completion of this study. We thank Mr Ben Kanagaratnam for his advice on the statistical analyses.

**About the authors**

Anna Gubbins is a 4th-year medical student at National University of Ireland, Galway. John Lally (MB, MRCPsych, PG Dip Clinical Education) is a Clinical Lecturer in Psychiatry and Colm McDonald (PhD MRCPsych) is Professor of Psychiatry at National University of Ireland, Galway; both work at West Galway Mental Health Services, Health Service Executive West.

**References**

3 Sukanta S, Chant D, McGrath J. A systematic review of mortality in schizophrenia is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123–31.
6 De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24: 412–24.
Crisis plans in a home treatment team before and after a quality improvement programme

Emily Tan, Andrew Higginbotham, Lorette McQueen, Kamaldeep Bhui

Aims and method To measure the take-up of formal crisis plans in a specialist home treatment team (HTT) serving an ethnically diverse urban population; and to implement a quality improvement programme and measure its impact on crisis plan completion. Two audits were completed of patients before and after the implementation of a quality improvement programme. Descriptive data are shown by ethnic group, by gender, and for people with multiple hospital admissions.

Results At baseline, 16.7% of patients at high risk of admission had an HTT crisis plan, compared with 26.7% of a comparison group. Only 23.1% of the crisis plans for patients with a history of frequent admission mentioned the prevention of future admissions. Crisis plan completion improved following the quality improvement programme, when 80.0% of discharges had an HTT crisis plan; of these, 73.0% mentioned admission prevention. In the follow-up audit, 22.7% of patients in the multiple admission group had been readmitted to hospital at least once. Crisis plan completion did not appear to differ by ethnic group or gender and did not appear to be related to hospital readmission.

Clinical implications Crisis plan completion improved with simple practical methods, but completion was unrelated to gender, ethnicity or later readmission.

Declaration of interest None.

Collaborative and person-centred crisis plans are part of mental health policy in the UK, but little work has investigated take-up of crisis plans or equity in their use by crisis resolution and home treatment teams (CRHTs). Crisis plans may be a useful tool in the prevention of future hospital admissions, and they are especially relevant for CRHTs that perform a central gatekeeping role for people at risk of admission to hospital. Previous evaluations of